News

Filter
Filter

07 / 10 / 2024

Perthera Names Marketing Veteran, Jeanne M. Cummins, Chief Marketing Officer (CMO)

Appointment Drives Growth and Market Expansion with Strategic Leadership for Perthera, a Pioneer in Precision Oncology Decision Support MCLEAN, VA // Perthera, The Therapeutic Intelligence Company® and the industry leader in Precision Oncology Decision Support, announces the appointment of industry veteran Jeanne M. Cummins as Chief Marketing Officer (CMO). Ms. Cummins will lead the company’s marketing initiatives to support its ambitious growth plans. This appointment marks a significant step in Perthera’s commercial development, following the assignment of a Category III CPT code for reimbursement in 2023. This recognition by the AMA was a pivotal moment, paving the way to make […]

Read More
Decision SupportThe Leadership Team
EIN Presswire PDF

05 / 31 / 2024

At ASCO ’24, Perthera Launches New Services Aimed at Easing Burden on Clinicians Delivering Precision Oncology Care

Chicago, IL – May 31, 2024 – Perthera has announced the addition of new services and capabilities to its Precision Oncology Platform suite aimed at making it easier for Oncologists to identify and deliver the best precision treatment for their patients.  The Perthera Precision Oncology Platform provides patented, AI-driven, ranked-therapy option decision support to oncologists, advocacy groups, and their staff. The addition of new capabilities makes it simpler to order a report and now come with an option to have Perthera handle the complex task of getting a patient on clinical trial or off-label therapy, if chosen by the treating […]

Read More
Decision SupportPrecision Oncology
EIN Presswire PDF

04 / 24 / 2024

Renowned Oncologist and Cancer Researcher, Dr. Derek Raghavan, Joins Perthera as Chief Medical Officer

Mclean, VA // Perthera, the industry leader in Precision Oncology Decision Support announces that Dr. Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, founding President of the Levine Cancer Institute and former Chair and Director of the Cleveland Clinic Taussig Cancer Institute, has joined Perthera as Chief Medical Officer (CMO). Dr. Raghavan’s appointment underscores Perthera’s commitment to advancing precision oncology and transforming decision making for oncologists, especially those practicing in a community setting, who are confronted by the ever-increasing complexity in making treatment decisions. “I look forward to helping Perthera reach the full potential of their best-in-class AI-based treatment decision support […]

Read More
Precision OncologyThe Leadership Team
EIN Presswire PDF

04 / 02 / 2024

Perthera Names HealthTech and Medical Marketing Veteran, Donna Tuths, as CEO

Appointment signals new phase of expansion for Perthera, a Pioneer in Precision Oncology Decision Support MCLEAN, VA // Perthera, the industry leader in Precision Oncology Decision Support announces the appointment of industry veteran Donna Tuths as Chief Executive Officer. Ms. Tuths will lead the company’s market expansion and will continue to scale product development and new services. This appointment signals a new phase in Perthera’s commercial development following the assignment of a Category III CPT code for reimbursement in 2023. “I’m excited to join Perthera at this pivotal time to drive expansion,” said Tuths. “Perthera has a vital role to play […]

Read More
Decision SupportPrecision OncologyThe Leadership Team
EIN Presswire PDF

01 / 18 / 2024

Precision Oncology Pioneer, Perthera, Presents Latest Research at ASCO GI 2024

Chicago, IL // In advance of a new Current Procedural Terminology (CPT) Category III code that will go into effect on July 1st, Perthera, the leader in AI precision oncology solutions, introduced its latest generation of clinical support tools, including Perthera Lab Direct and Perthera RWE Navigator. As part of this new, enhanced clinician experience, Perthera Lab Direct will make it easier to order reports, delivering results faster and the Perthera RWE Navigator will provide clinicians direct access to Perthera’s powerful analytics. The Category III CPT code provides a critical pathway to reimbursement and wider adoption of AI-assisted Oncology decision support. The new multi-ordering platform and expanded analytics bench are intended to help support increased clinician demand.

Read More
AIClinical ResearchDecision SupportPrecision OncologyRWE
PR Newswire PDF

06 / 02 / 2023

At ASCO ’23, AI Precision Oncology Company Perthera Unveils Premium Experience for Clinicians with New Options for Ordering and Access to Enhanced Perthera Analytics

Chicago, IL // In advance of a new Current Procedural Terminology (CPT) Category III code that will go into effect on July 1st, Perthera, the leader in AI precision oncology solutions, introduced its latest generation of clinical support tools, including Perthera Lab Direct and Perthera RWE Navigator. As part of this new, enhanced clinician experience, Perthera Lab Direct will make it easier to order reports, delivering results faster and the Perthera RWE Navigator will provide clinicians direct access to Perthera’s powerful analytics. The Category III CPT code provides a critical pathway to reimbursement and wider adoption of AI-assisted Oncology decision support. The new multi-ordering platform and expanded analytics bench are intended to help support increased clinician demand.

Read More
AIDecision SupportPrecision OncologyRWE
PR Newswire PDF

02 / 08 / 2023

Perthera.ai Announces a Category III CPT Code from the AMA for its Patented Precision Oncology Decision Support Platform

McLean, VA // Perthera.ai, the industry leader in Oncology Decision Support, announces the release by the American Medical Association of a new Current Procedural Terminology (CPT) Category III code, 0794T, clearly recognizing the increasing importance of AI-assisted decision support in delivering precision oncology care. Perthera.ai is a pioneer in personalized AI-assisted Oncology decision support with its patented ranked therapy options presented in the Perthera Report created by our Precision Oncology Platform.

Read More
AIDecision SupportPoint of CarePrecision Oncology
NewsWires AMA Category III Codes PDF

10 / 10 / 2022

Massive Bio and Perthera.ai Partner to Empower Cancer Patients with Personalized Therapies and Accurate Trial Recommendations

New York, NY & McLean, VA // Massive Bio has announced a partnership with Perthera.ai. Perthera.ai’s ranked therapy recommendations will complement Massive Bio’s screening and analysis to aid more cancer patients in finding an appropriate clinical trial.

Partnerships
Applied Clinical Trials Business Wire

06 / 08 / 2022

ACCRU, a Cancer Research Network Operating Within the Mayo Clinic, has Officially Partnered with Perthera

A leading precision oncology company, to bring innovative clinical trials to cancer patients throughout the country in the Target Panc Program. Perthera, with its Oncology Operating System™, will serve as the centralized “Molecular CRO” under the umbrella protocol.

Partnerships
ACCRU PDF

06 / 06 / 2022

ASCO ’22: Perthera Announces the Immediate Availability of the Perthera AI Analytics Platform to Cancer Centers for Improved Analytics, Clinical Trial Optimization and Patient Care Management

Chicago, IL // For the first time, Perthera AI’s proven data mining, analytics, optimization and care management platform is now available as an analytics solution for cancer centers to utilize with their own patient data, at no cost. A research study by Cedars Sinai, PanCAN and Perthera’s GIPOCS program was one of the first to utilize data from Perthera’s Analytics solution and was presented at ASCO ‘22.

AIClinical TrialsDecision SupportPrecision OncologyRWE
PDF

THIS IS AI-POWERED PRECISION ONCOLOGY

Contact Us